Biotest AG
BIO3
ISIN DE0005227235 / Valor 325670
Biotest AG
UMushroom community rating:
About company
Biotest AG is a biotechnology company that develops, manufactures, and markets biological products for the treatment of blood and immune system disorders.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (06.11.2025):
Biotest AG’s Full Year 2024 report highlights solid financial performance with 6.1% sales growth to €726.2 million and EBIT at the upper end of guidance at €94.5 million, while maintaining a robust operating cash flow of €60.9 million. The report also underscores important operational milestones, including key regulatory approvals that support the company’s long‐term growth strategy.
Financial Growth
For Full Year 2024, Biotest AG achieved sales growth of 6.1%, increasing revenue from €684.6 million in FY 2023 to €726.2 million, with EBIT reaching €94.5 million in line with upper guidance levels.
Cash Flow Strength
The operating activities generated a positive cash flow of €60.9 million in FY 2024, demonstrating strong financial discipline and operational efficiency.
Operational Milestones
Key regulatory successes, such as the FDA approval of Yimmugo® and successful GMP inspections for both Yimmugo® and fibrinogen, further enhance Biotest AG’s position to support sustainable long-term growth and future earnings prospects.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
728 M
Market cap (USD)
Daily traded volume (Shares)
27.1 / 26.4
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
